Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOTA-STR-17126 Theranostic Pair in Advanced or Metastatic Cancer
NCT07608848Phase 1Recruiting
- Sponsor
- Integrated Haematology and Oncology Network
- Start
- May 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]Ga-DOTA-STR-17126 and [177Lu]Lu-DOTA-STR-17126 in breast cancer and prostate cancer (PCa), sponsored by Integrated Haematology and Oncology Network. Primary endpoint: Number of participants with adverse events (AEs), serious adverse events (SAEs), abnormal laboratory parameters, and abnormal physical examinations findings at Day 43. Started May 2026; status: recruiting.
02
Drugs
[68Ga]Ga-DOTA-STR-17126[177Lu]Lu-DOTA-STR-17126
03
Conditions
breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT07608848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07608848.